Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles

Lin, You Zhe; Shen, Yi; Wu, Wan Rong; Wang, Wei‐Jan; Wang, Yuan Liang; Lin, Chen; Hung, Mien Chie; Wang, Shao‐Chun

doi:10.3390/ijms22136938

Cited by 10 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study shows that imatinib inhibits SARS-CoV-2 in a luciferase-based pseudoparticle entry assay in Vero E6 cells ( 37 ). Moreover, chronic myeloid leukemia patients treated with imatinib show low numbers of COVID-19 cases ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, we found that amuvatinib efficiently blocked SARS-CoV-2 replication with no cytopathic effect in Vero E6 cells. Previous study shows that imatinib, another tyrosine kinase inhibitor, blocks SARS-CoV-2 infection by reducing the expression of ACE2 ( 37 ). Here, we showed that not only imatinib, but also amuvatinib, displayed antiviral activity against SARS-CoV-2 infection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Rapamycin is an autophagy activator, and its anti-inflammatory action is explained by the inhibition of the NF-κB proinflammatory signalling pathway [27,28]. Also, tyrosine kinase inhibitor (imatinib) has also been recognized as a potent inhibitor of NF-κB signalling and inflammation in vivo and in vitro [29,30].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical neuroinflammatory markers in the hippocampus of PTZ-kindled rats under conditions of rapamycin and axitinib treatment

Poshyvak

Pinyazhko

Godlevsky

et al. 2023

SR: PS

View full text Add to dashboard Cite

The aim of the study is to determine the level of HIF-1α, TNF-α, and NF-kB in the hippocampus of kindled rats treated with rapamycin and axitinib. Materials and methods. Kindling was produced in 29 rats by administration of three-week pentylenetetrazole (PTZ, 35.0 mg/kg, i.p.). Treatment with rapamycin (0.5 mg/kg, i.p.) and axitinib (2.5 mg/kg, i.p.) was performed for ten days in fully kindled rats. The avidin-biotin-peroxidase method was used for hippocampal slice staining. For negative control, staining was performed using only secondary antibodies. Results. The HIF-1α expression increased in kindled rats raised by 1.77 times compared to the control (p<0.001). Axitinib treatment resulted in of HIF-1α level of 16.7 % (p<0.05) compared with kindled animals, while combined treatment with rapamycin and axitinib reduced HIF-1α by 33.8 % (p<0.01). In kindled rats, TNF-α expression was 3.74 times greater than in control (p<0.001). Rapamycin treatment reduced TNF-α by 31.0 % (p<0.01). Axitinib treatment caused a reduction of TNF-α by 21.1 % (p<0.05). Combined treatment with rapamycin and axitinib reduced TNF-α by 48.0 % (p<0.001) but still exceeded the TNF-α in control by 1.95 times (p<0.01). NF-kB level in kindled rats exceeded the control by three times (p<0.001). Rapamycin caused a reduction of 19.3 % (p>0.05), while axitinib – by 26.5 % (p<0.05) compared with kindled rats. Combined treatment with rapamycin and axitinib resulted in NF-kB reduction by 56.7 % compared with kindled rats (p<0.001). Conclusions. PTZ-kindling resulted in an increase in the immunoreactivity of HIF-1α, TNF-α, and NF-kB in the hippocampus. Combined treatment with rapamycin and axitinib engendered prevention of generalized seizures and normalized the level of HIF-1α and NF-kB with a significant reduction of TNF-α. Effects of treatment favours of synergy action of rapamycin and axitinib

show abstract

“…A recent in vitro study conducted by Lin et al showed that imatinib can effectively prevent SARS‐CoV‐2 infection with low toxicity. 73 Morales‐Ortega et al 40 in a study monitored the COVID‐19 patients treated with imatinib. Seventeen of 20 patients recovered and three patients died.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, Zhao et al 41 indicated that imatinib had no inhibitory effect on SARS‐CoV‐2 infection. A recent in vitro study conducted by Lin et al showed that imatinib can effectively prevent SARS‐CoV‐2 infection with low toxicity 73 . Morales‐Ortega et al 40 in a study monitored the COVID‐19 patients treated with imatinib.…”

Section: Discussionmentioning

confidence: 99%

Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence

Amani

Zareei

Amani

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background and Objective Despite the pervasive vaccination program against coronavirus disease 2019 (COVID‐19), people who got fully vaccinated are still contaminated by severe acute respiratory syndrome coronavirus 2, making an effective and safe therapeutic intervention a crucial need for the patients' survival. The purpose of the present study is to seek available evidence for the efficacy and safety of three promising medications artesunate, imatinib, and infliximab against COVID‐19. Methods A literature search was conducted in PubMed, Cochrane Library, medRxive, and Google Scholar, and the relevant articles published up to January 2022 were found. Furthermore, the clinical trial databases were screened for finding more citations. Data analysis was carried out applying The Cochrane Collaboration tool and Newcastle–Ottawa scale to assess the included studies. Meta‐analysis was performed using RevMan 5.4.1. Results Five published studies were identified as eligible. Meta‐analysis showed that there was no significant difference between the infliximab and control groups in terms of mortality rate (risk ratio [RR]: 0.65; confidence interval [CI] 95%: 0.40–1.07; p = .09). However, a significant difference was observed between the two groups for the hospital discharge (RR: 1.37; CI 95%: 1.04–1.80; p = .03). No remarkable clinical benefit was observed for using imatinib in COVID‐19 patients. Artesunate showed significant improvement in patients with COVID‐19. Conclusion In the present, limited evidence exists for the efficacy and safety of artesunate, imatinib, and infliximab in patients with COVID‐19. The findings of WHO's Solidarity international trial will provide further information regarding these therapeutic interventions.

show abstract

Imatinib (STI571) Inhibits the Expression of Angiotensin-Converting Enzyme 2 and Cell Entry of the SARS-CoV-2-Derived Pseudotyped Viral Particles

Cited by 10 publications

References 20 publications

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle

Immunohistochemical neuroinflammatory markers in the hippocampus of PTZ-kindled rats under conditions of rapamycin and axitinib treatment

Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence

Contact Info

Product

Resources

About